timal timal medical practice. Comparative trials are the only means allowing an assessment between competing therapeutic options (1). Scientifically valid clinical trials which ask clin ically meaningful questions and which are well-designed and appropriately executed may have a profound impact on clinical medicine. A few examples of such studies which immediately have influenced care in infectious diseases include the initial studies of vidarabine in herpes encephalitis (2) . the efficacy of polio vaccine (3) and the primary prevention of rheumatic fever with penicillin for streptococcal pharyngitis (4) . Most aspects of clinical practice, however. have not been validated by appropriate clinical trials.
Multicentre clinical trials are undertaken when one centre cannot enroll sufficient study subjects within a predetermined time frame to ensure scientific validity. A multicentre study increases the complexity of a clinical trial by requiring standardization of the study: this requires intensive monitori ng and (usually) greatly increases cost.
Currently there is limited funding available to support clinical research. While some studies are funded through National Institutes of Health. National Health and Welfare Research and Development Proaram. local agencies and. less frequently. the Medical Research Council, the majority of mu lticentre clinical u;als are funded through the pharmaceutical industry. Pharmaceutical sponsored studies may provide important insights. For antimicrobials. however. many are 'off the mark' with respect to clinical appropriateness of therapeutic regimens being compared. This reflects the fact that such studies generally are undertaken to obtain licensing indications for a particular antimicrobial. not primarily to answer relevant clinical questions.
The Clinical Trials Subcommittee of the Canadian Infectious Diseases Society has promoted the development and execution of multicentre clinical trials within
the Canadian Infectious Diseases Society fo r over 10 years. A number of publications have resu lted from studies undertaken tl1rough the auspices of this subcommittee (5-1 0). The majority of these h ave been p h armaceutically funded studies, with som e sponsored jointly witl1 the National Cancer Institu te of Canada. Important observations have been made by these studies . A persistent problem, however, is how to address the many important clinical issu es in infectious diseases which. because they do not address qu estions relevant to a pharmaceutical marketing strategy. do not attract funding.
In this issue of the Journal, a collection of five workshop summaries from a clinical trials meeting of the Canadian Infectiou s Diseases Society in February 1991 is published (page 75). The goals of these sessions were to identiJY potential important questions relating to infectious diseases which could be answered through multicentre clinical trials in Canada. The workshop titles were not inclusive; they were selected as rep resentative and important tl1emes from which to develop lin1ited objectives. The summaries-which demonstrate different approaches in different workshops -document the diversity of problems and tl1e interests of the Canadian infectious diseases com mun ity.
A recurring theme through all of the workshops is U1e need for development of Canadian databases for infectious diseases. We rely heavily. almost exclusively in fact. on data generated p i;marily in the United States and occasionally Europe. and extrapolate this infom1a-tion to tl1e Canadian tl1eatre. Unique features in tl1e epidemiology of infectious d iseases in Canada. seasonal variations and funding of the health care system mean that this approach is not necessarily. or even usually. vali d. Thus there was a general feeling tl1at registries and other databases need to be developed to identify disease occurrence and manifestations of important infections in clinical practice in Canada. While the laboratory Centre for Disease Control, and provincial and territorial health departments fulfill some of this in Ed itoria l s urveillance of selected infections. the diseases identified by the public h ealth surveillance n etwork are gen erally uncommon (with the exception of sexually transmitted agents) . Wha t is the Cana dian occurren ce of prosthe tic infections? Of d isseminated fungal infections in granulocytopenic p a tients? Of brain a bscess? One s u ch databa se , des c ribing retros p ectively the u se of ribavirin in p edia trics, h a s already been collected a nd presen ted (11) . This report wa s the first outcome from this clinical trials meeting.
The February m eeting was u n qu estionably a u seful experience and enthusiastically s upported by participants . Th e s u ccess of this meeting, h owever. will be measured by clinical trial development in Canada based on these discussion s. The p rob lems of funding for m ulticentre clinical trials. p articularly in the cu rrent highly com petitive research environment with limited fu nds available, and of committmen t by personnel wh o are already overcommitted remain. The workshop s u mmaries, h owever, serve as indica tors of the variety a nd com plexity of, and the n eed for , m u lticentre clinical trials in infectious diseases in Canada. It is to be h oped that this Jouma l will have the opport u n ity to p ublish stu dies resulting from th ese discu ssion s over the n ext several years.
T hese workshop s were sponsored by a grant fro m
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